The editorial team of the European Journal of Neurology welcomes two new colleagues, starting in January 2022. Alessandro Tessitore and Barbara Borroni have both joined as Associate Editors.
EAN Invites You to Join the Challenge: 24 Days, 24 Modules!
December 22, 2025
From 1 January 2026, the 24 Days, 24 Modules: eanCampus Challenge invites neurologists worldwide — EAN members and non-members alike — to access 24 high-quality neurology modules for free.
EAN 2026 Congress Quiz – Your Chance to Win Free Registration
December 9, 2025
Hit Headlines With Your EAN 2026 Abstract
December 1, 2025
Latest Posts
-
-
Breaking news
Study of mirtazapine for agitated behaviors in dementia (SYMBAD): a randomised, double-blind, placebo-controlled trial
December 9, 2021This parallel-group, double- blind, ransomised, placebo-controlled trial conducted in 26 United Kingdom centres, investigated the efficacy and tolerability of mirtazapine versus placebo in treating agitation in patients with probable or possible Alzheimer’s disease. -
Breaking news
The impact of smoking cessation on multiple sclerosis disease progression
December 9, 2021This study investigated the potential benefits of smoking cessation in slowing down clinical progression in patients with multiple sclerosis. -
Breaking newsCOVID-19
C-reactive protein and white matter microstructural changes in COVID-19 patients with encephalopathy
December 9, 2021Twenty patients hospitalized with COVID-19 encephalopathy were included in this retrospective cohort study. -
Breaking newsCOVID-19
Transient sensory symptoms among first-dose recipients of the BNT162b2 mRNA COVID-19 vaccine: A case-control study
December 7, 2021In this case-control study, the authors evaluated NSSS from a cohort of 7,812,845 BNT162b2 first-dose recipients, of whom 10,929 reported an adverse event following immunization. -
This narrative review was conducted to collect and discuss published data about neurological side effects of SARS-CoV-2 vaccines in order to discover type, frequency, treatment, and outcome of these side effects.
-
Breaking newsCOVID-19
COVID-19 Vaccination Reactogenicity in Persons With Multiple Sclerosis
December 7, 2021The objective of this retrospective cross-sectional study was to generate real-world multiple sclerosis–specific vaccine safety information, particularly in the context of specific DMTs, and provide information to mitigate specific concerns in vaccine hesitant PwMS. -
Breaking newsCOVID-19
Multifocal and Microvascular Involvement in Ischemic Stroke During COVID-19: A Cohort Study With Comparison With Non-COVID-19 Stroke
December 7, 2021This single-center retrospective observational study compared stroke characteristics between patients with and without COVID-19. -
Breaking newsCOVID-19
Headache as a Symptom of COVID-19: Narrative Review of 1-Year Research
December 7, 2021In this article the author sought to highlight the most remarkable findings concerning headache secondary to COVID-19, specifically focusing on epidemiology, characteristics, pathophysiology, and treatments. -
Breaking newsCOVID-19
Incidence and Predictors of Thrombotic Complications in 4742 Patients with COVID-19 or Other Acute Infectious Respiratory Diseases: A Propensity Score-Matched Study
December 7, 2021In this study the authors retrospectively studied 4742 patients with acute infectious respiratory disease (AIRD); 2579 were diagnosed to have COVID-19 and treated with heparin, whereas 2163 had other causes of AIRD. -
Breaking newsCOVID-19
Infection of Brain Pericytes Underlying Neuropathology of COVID-19 Patients
December 7, 2021In this article the authors used state-of-the-art multiplexed immunostaining of human brains and demonstrated that expression of the SARS-CoV-2 receptor ACE2 is restricted to a subset of neurovascular pericytes. -
Breaking newsCOVID-19
Analysis and Identification Genetic Effect of SARS-CoV-2 Infections to Alzheimer’s Disease Patients by Integrated Bioinformatics
December 7, 2021In this article the authors aimed to explore the interaction between COVID-19 and Alzheimer's disease by integrating bioinformatics to find the biomarkers which lead to AD occurrence and development with COVID-19 and provide early intervention. -
Breaking newsCOVID-19
Impact of COVID-19 on ‘Living Well’ with Mild-to-Moderate Dementia in the Community: Findings from the IDEAL Cohort
December 7, 2021In this article the authors aimed to explore the impact of the pandemic on community-dwelling individuals with mild-to-moderate dementia and compare responses with pre-pandemic data. -
Breaking newsCOVID-19
Clinical features and cognitive sequelae in COVID-19: a retrospective study on N=152 patients
December 7, 2021This work aimed at exploring how post-infective cognitive status relates to clinical/treatment outcomes by controlling for premorbid/current risk factors for cognitive deficits. -
Breaking newsCOVID-19
Prevalence of depression, anxiety, and psychological distress in patients with epilepsy during COVID-19: A systematic review
December 7, 2021The purpose of this systematic review study was to investigate the epidemic effect of COVID-19 on increasing the prevalence of mental disorders such as depression, anxiety, and sleep disorders in people with epilepsy.









